Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Date:3/8/2011

NEW YORK, March 8, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2010.

At December 31, 2010, the Company had cash, cash equivalents, interest receivable, and investment securities of $28.5 million, as compared to $35.9 million at December 31, 2009.  

The net loss for the fourth quarter ended December 31, 2010 was $5.3 million, or $0.09 per share, compared to a net loss of $4.7 million, or $0.08 per share, for the comparable quarter in 2009, representing an increase in net loss of $0.6 million.  Other research and development expenses increased by $2.6 million, as compared to the fourth quarter of 2009, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The fourth quarter of 2009 included a $1.5 million one-time research and development expense related to a terminated early-stage pipeline product candidate, which accounts for the net increase in other research and development expenses of $1.1 million as compared to the fourth quarter of 2009.

The net loss for the year ended December 31, 2010, was $20.3 million, or $0.34 per diluted share, compared to net income of $10.5 million, or $0.21 per diluted share, for the year ended December 31, 2009.  The change in net (loss) income was primarily attributable to a $21.6 million decrease in license revenue and a $3.6 million decrease in other revenue.  License revenue in the year ended December 31, 2009 was related to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii) which eliminated the C
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
2. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
6. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
7. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  EnteroMedics Inc. (NASDAQ: ... technology to treat obesity, metabolic diseases and other gastrointestinal ... call on Thursday, August 7, 2014 at 11:00 AM ... quarter ended June 30, 2014 and to provide a ... The second quarter conference call may be accessed by ...
(Date:7/29/2014)... Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today reported net income for the quarter ended ... share, and non-GAAP net income of $94.0 million, or $0.88 ... year earlier was $93.3 million, or $0.81 per diluted share, ... diluted share.  Net sales for the quarter ...
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. ... and drug candidates targeting specific pathogens that cause serious ... the unusual market activity in the Company,s stock, the ... accordance with its usual practice. The Company stated that ... activity. About Synthetic Biologics, Inc. ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... New soluble polymer material,designed to stop bone bleeding ... new animal study just published in the Annals of ... recently published,research showing that the use of the new ... from the Medical University of South Carolina at Charleston,and ...
... AG (,Intercell,) to acquire Iomai Corporation (,Iomai,) in ... per share of Iomai,s common stock ... of approximately USD 189 million (EUR ... exchange for approximately 41 percent of Iomai,s ...
Cached Medicine Technology:Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July 29, 2014 (HealthDay ... stage for harmful health habits, including eating disorders, according to ... to 2012 also found a link between early dieting and ... was when she started her first diet, the more likely ... like vomiting or laxative misuse," said study researcher Lauren Holland, ...
(Date:7/30/2014)... Researchers from the University of So Paulo (USP) have ... no instructions for the production of a protein, modulates ... of apoptosis, or programmed cell death. , According ... and coordinator of a research funded by So Paulo ... cancer cells, and methods that are capable of stimulating ...
(Date:7/30/2014)... We know pregnancy cravings don’t always inspire the ... cream—but the latest episode of the Telly Award-winning web series ... has a recipe that is delicious, satisfying and, most of ... serves up an easy recipe that supports a healthy diet ... Rasika, which was named one of the 20 top-rated restaurants ...
(Date:7/30/2014)... Chinese researchers say a protein that makes up ... used as a prognostic indicator in people on chemotherapy for ... article on the study , just posted on the Surviving ... Medicine at Shandong University Hospital in China analyzed the albumin ... 1995 and 2013. They found that, the lower the albumin ...
(Date:7/30/2014)... Seattle, Wa (PRWEB) July 30, 2014 It is ... as they would want to be in life is because they ... However, as recent research shows, this belief is only an ... they can achieve more had they been only “smarter”. , So, ... but also by one’s willingness to work hard for that success. ...
Breaking Medicine News(10 mins):Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3Health News:Brazilian researchers identify RNA that regulates cell death 2Health News:Brazilian researchers identify RNA that regulates cell death 3Health News:What to Eat When You’re Expecting 2Health News:Study Finds Common Blood Protein May Predict Mesothelioma Survival, Reports Surviving Mesothelioma 2Health News:Brain Evolution System - #1 Brainwave Entrainment Meditation Program Review | Unleashing One’s Ultimate Potential Improving Mind Power – Vinamy 2Health News:Brain Evolution System - #1 Brainwave Entrainment Meditation Program Review | Unleashing One’s Ultimate Potential Improving Mind Power – Vinamy 3
... Bavarian Nordic,reports the successful completion of a ... who received either one or two doses of,IMVAMUNE(R) ... are seen as the pivotal step on the ... in order to achieve a BLA for healthy,subjects., ...
... CHICAGO, Nov. 29 , What: Join Zoraida Sambolin, co-anchor of the ... and Easter Seals at the 2007 Easter Seals Metropolitan ... event that benefits local Chicago programs ... with autism, including the new Therapeutic School and Center ...
... to lamotrigine use, research shows , THURSDAY, Nov. 29 ... drug lamotrigine in pregnant women with epilepsy can help reduce ... Lamotrigine, an epilepsy drug, is taken by pregnant women with ... defects. However, the drug has also been linked to increased ...
... this to a human ,fountain of youth, however , , THURSDAY, ... able to temporarily return old skin cells to their youthful ... "This gene gets more and more active with age," said ... at Stanford University. "It doesn,t exist to make us ...
... report the discovery of biological markers of prostate cancer ... shedding light on the genetic basis for the prostate ... is being presented today at the American Association for ... Disparities in Racial/Ethnic Minorities and the Medically Underserved, being ...
... A study led by a University of Pennsylvania biologist in ... widely held belief that mice are the main animal reservoir ... published in the Proceedings of the Royal Society B, demonstrates ... the four species that account for major outbreaks. , According to ...
Cached Medicine News:Health News:Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate 2Health News:Easter Seals Festival of Trees Holiday Gala Will Make a Difference for Children and Adults With Autism 2Health News:Tracking Drug Levels Helps Pregnant Women With Epilepsy 2Health News:Gene Tweak Reverses Aging in Mouse Skin Cells 2Health News:Biological markers of prostate cancer shed light on cancer burden faced by African-American men 2Health News:University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: